Related Experiment Video
Updated: Jun 5, 2026

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents (HPHC)
Published on: May 10, 2016
AI snake oil? A risk/benefit analysis for toxicology
Thomas Hartung1,2,3, Mohan Rao4, Mamta Behl5
1Doerenkamp-Zbinden Chair for Evidence-Based Toxicology, Center for Alternatives to Animal Testing (CAAT), Johns Hopkins University, Baltimore, MD, United States.
None:
Artificial intelligence (AI) is increasingly used to support predictive, mechanistic, and human-relevant toxicology at scale. However, its integration into regulatory science - particularly in drug development - remains uneven, because encouraging technical performance has not yet translated automatically into regulatory trust. Representative AI toxicology studies now span datasets from roughly 103 chemicals to >3 × 104 peptide or chemical records and report performance ranging from modest in prospective screening settings to strong on narrower, well-curated endpoints. This manuscript presents a critical analysis of the dual nature of AI in toxicology. We review the state of the art in AI-enabled applications, ranging from Green Toxicology and the Human Exposome to specific challenges in safety assessment for biologics and synthetic peptides. Particular attention is given to the gap between rapid model development and regulatory acceptance, highlighted by the challenges of model interpretability, dataset bias, insufficient external validation, and the assessment of complex endpoints like immunogenicity. To navigate these complexities, we discuss the next-generation "e-validation" framework and emphasize the TREAT principle - Trustworthiness, Reproducibility, Explainability, Applicability, and Transparency - as a foundation for building regulatory trust. We hypothesize that AI-based methods in toxicology can achieve regulatory acceptance when they satisfy the TREAT criteria and undergo continuous e-validation within a clearly defined context of use. This framework distinguishes credible AI applications from "snake oil" by establishing measurable criteria for trust-building, including dataset provenance, external validation, uncertainty characterization, and life-cycle monitoring. We argue that AI is neither a miracle cure nor a technological illusion, but a powerful evidence engine that can contribute to a more predictive and ethical toxicological science when it is rigorously validated.
More Related Videos
05:27Gap Junctional Intercellular Communication: A Functional Biomarker to Assess Adverse Effects of Toxicants and Toxins, and Health Benefits of Natural Products
Published on: December 25, 2016
11:28Analysis of Iophenoxic Acid Analogues in Small Indian Mongoose (Herpestes Auropunctatus) Sera for Use as an Oral Rabies Vaccination Biological Marker
Published on: May 31, 2019
Related Concept Videos
Toxicity Testing in Animals
Drug Toxicity: Dose-Dependent Reactions
Drug Toxicity: Overview
Toxicokinetics: Overview
Drug Regulation
Dose Response Curve: Conventional Versus Nonmonotonic